US · Healthcare · Biotechnology
EPS came in at 0.28 against a street estimate of 0.18 — a beat of 55.6%.
Analysts rate Aurinia Pharmaceuticals Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $17.86.
| Fund | Stake |
|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.19% |
| BlackRock Inc | 5.90% |
| NEA Management Company, LLC | 2.98% |
| Two Sigma Investments LLC | 2.61% |
| Arrowstreet Capital Limited Partnership | 2.47% |
| State Street Corp | 1.90% |
| Morgan Stanley - Brokerage Accounts | 1.68% |
| Marshall Wace Asset Management Ltd | 1.41% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 AURINIA PHARMACEUTICALS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial figures disclosed in this filing • Filing date: August 19, | 2026-08-19 |
| Quarterly report · Q2 2026 AURINIA PHARMACEUTICALS INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net product sales (6 months): $152.975 million vs. $126.545 million (2 | 2026-08-06 |
| Results announced · Q3 2026 AURINIA PHARMACEUTICALS INC. — H1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $160.9 million, up 21% from $132.5 million in | 2026-08-06 |
| Shareholder vote results · Q2 2026 AURINIA PHARMACEUTICALS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held virtually on June 3, 2026 • Total shares voted: a | 2026-06-04 |
| Acquisition completed · Q2 2026 AURINIA PHARMACEUTICALS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $6.955 per share in cash, plus one contingent value right (CVR | 2026-05-11 |
| Quarterly report · Q1 2026 AURINIA PHARMACEUTICALS INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product sales: $73.6 million (Q1 2026) vs. $60.0 million (Q1 2025) — incr | 2026-05-07 |
| Proxy statement · Q2 2026 AURINIA PHARMACEUTICALS INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect Five Directors — Kevin Tang, Jeffrey | 2026-04-21 |
| Annual report FY2025 AURINIA PHARMACEUTICALS INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net product sales for 2025: $271.3 million, up 25% from $21 | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Kezar Life Sciences for $6.955 per share plus CVR Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences on May 11, 2026. Aurinia acquired all outstanding Kezar shares through a tender offer at $6.955 per share in cash plu | 2026-05-11 |
| Agreement and plan of merger with another pharmaceutical company announced Aurinia Pharmaceuticals Inc. has agreed to acquire Kezar Life Sciences, Inc. through a merger agreement dated March 30, 2026. Under the deal structure, Aurinia Pharma U.S., Inc. will merge w | 2026-04-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aurinia Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.